Navigation Links
Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
Date:12/6/2007

SOUTH SAN FRANCISCO, Calif., Dec. 6 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the development of monoclonal antibody therapeutics (MAbs) for cancer, today announced that Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has exercised an option to extend its evaluation of selected Raven MAb antibodies. As a result, Raven will receive an undisclosed milestone payment.

Under an agreement announced in January 2007, Wyeth has the option to obtain an exclusive license to develop and commercialize selected MAbs from Raven's portfolio of antibodies to a specified target.

The antibodies included in the agreement were discovered using Raven proprietary immunization technology and tumor-derived stem-cell lines and were screened to select antibodies that are active alone or in a conjugated form.

"We look forward to continuing our agreement with Wyeth, a company with a strong commitment to oncology research and development," said George F. Schreiner, M.D., Ph.D., Raven's Chief Executive Officer. "Raven has multiple anti-cancer antibody drug candidates in our pipeline, and collaborations such as this are a critical part of our strategy to rapidly advance the most promising candidates into the clinic."

About Raven

Raven biotechnologies, inc. (http://www.ravenbio.com) is a privately held biotechnology company focused on the development of monoclonal antibody therapeutics for treating cancer. Raven's lead product candidate, RAV12, targets adenocarcinomas and is in clinical development for the treatment of gastrointestinal and other cancers. Raven's discovery process simultaneously identifies cell-surface d
'/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
2. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
3. Maven Biotechnologies, LLC to Present at BIOCOM Investor Conference
4. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
5. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
6. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
7. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
8. Wyeth Announces Election of New Principal Corporate Officer
9. Wyeth Declares Preferred Stock Dividend
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2014)... NY (PRWEB) July 20, 2014 ... custom quartz glass optics, and spectrophotometer calibration ... these years, NSG has released many products that ... successful product has been their solid-state calibration standards. ... liquid standards since their release in 2008. ...
(Date:7/18/2014)... 2014 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced ... and operating results on Tuesday, August 5, 2014, before ... a conference call and simultaneous webcast at 8:30 AM ... InformationTo access this call, dial (888) 660-6127 (U.S.) or ... be accessed from the ,Events and Presentations, page of ...
(Date:7/18/2014)... Researchers at the University of Illinois at Urbana-Champaign ... pillar-bowtie nanoantennas (pBNAs) can be used like traditional ... are much smaller than the wavelength of light ... red light). A standard optical microscope acts as ... film. , "Unlike conventional photographic film, the effect ...
(Date:7/18/2014)... Reflecting the importance of the evolution of ... Rankin, the founder and president of Customized Real ... a fresh new approach to the firm’s branding. , ... influence the success of his or her commercial clients have ... of the first in this market to fully embrace the ...
Breaking Biology Technology:How NSG Precision Cells Spectrophotometer Calibration Standards Makes NIR Work Easier 2How NSG Precision Cells Spectrophotometer Calibration Standards Makes NIR Work Easier 3'Nanocamera' takes pictures at distances smaller than light's own wavelength 2LEED AP Certified ITRA Global / Customized Real Estate Services Introduces New Approach to Its Branding 2
... N.J., Nov. 4 Cambrex,Corporation (NYSE: CBM ) reports third ... (Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO ), -- Sales increased ... third quarter 2007. -- Adjusted EBITDA for the quarter was ... $9.7 million last year. -- Debt, net of cash was ...
... - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced ... pursue a pivotal (Phase II/III) randomized trial ... refractory,patients with head and neck cancers. The ... by the Company,s Board of Directors from ...
... Md., Nov. 4 PharmAthene, Inc.,(NYSE Alternext US: ... and chemical threats, announced today,that David P. Wright, ... at the Rodman and Renshaw 10th Annual Healthcare ... beginning at 2:25 p.m. E.T. in the,Holmes II ...
Cached Biology Technology:Cambrex Reports Third Quarter 2008 Results 2Cambrex Reports Third Quarter 2008 Results 3Cambrex Reports Third Quarter 2008 Results 4Cambrex Reports Third Quarter 2008 Results 5Cambrex Reports Third Quarter 2008 Results 6Cambrex Reports Third Quarter 2008 Results 7Cambrex Reports Third Quarter 2008 Results 8Cambrex Reports Third Quarter 2008 Results 9Cambrex Reports Third Quarter 2008 Results 10Cambrex Reports Third Quarter 2008 Results 11Cambrex Reports Third Quarter 2008 Results 12Cambrex Reports Third Quarter 2008 Results 13Cambrex Reports Third Quarter 2008 Results 14Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial 2
(Date:7/21/2014)... Growers of annual bedding plant seedlings or plugs ... a large stem diameter and high root dry ... during shipping and transplant. To achieve these desirable ... on supplemental lighting from high-pressure sodium lamps during ... diodes (LEDs) can give greenhouse growers other lighting ...
(Date:7/21/2014)... their cells are stressed when facing temperature extremes. Worse ... in the cell are slowed down more than others, ... of whack. Yet, those cells manage to keep their ... Rochester and the European Molecular Biology Laboratory have found ... of proteins is a key process in all cells, ...
(Date:7/20/2014)... A study of 473 sets of twins followed since ... of 24-month-old identical twins had language delay compared to ... the rate of late language emergence of single-born children. ... , The results of the study were published in ... Hearing Research . , University of Kansas Distinguished ...
Breaking Biology News(10 mins):LEDs shine in bedding plant production study 2When temperatures get cold, newly-discovered process helps fruit flies cope 2Large twin study suggests that language delay due more to nature than nurture 2Large twin study suggests that language delay due more to nature than nurture 3
... things that exist underground, plant roots are out-of-sight and ... plant parts are more familiar, plant roots are equally ... crop, and dazzling ornamental lies a root system that ... for plants, extract water and nutrients from soil, and ...
... Since the terrorist attacks of 2001, the Bureau of ... water and power to millions of people, has invested ... protect its facilities and personnel, says a new report ... better communication among security staff, regional and area office ...
... WI, AUGUST 18, 2008 Serpentine soils contain highly ... farming. Successful management of serpentine soils requires accurate measurement ... in the Soil Science Society of America Journal ... accurately measure calcium content in serpentine soils. To ...
Cached Biology News:Getting to the root of the matter 2National Research Council report on security at federally managed dams 2National Research Council report on security at federally managed dams 3